← Evidence map

ReviewToxins2016

Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.

Francesco ScaglionePubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

93 papers cite itlatest 60 shown

2016
…
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT04794504phase 264 enrolled2021
Full record →Abstract, authors, funding and every citing paper · PMID 26959061